Saadet Aydın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saadet Aydın has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Ömer Işık
Department of Cardiology, Fırat University, Elazığ, Turkey
4 shared publications - Ajar Koçak
Department of Cardiology, Faculty of Medicine, Ufuk University, Ankara 06836, Türkiye
3 shared publications - Berkay Ekici
Department of Cardiology, Faculty of Medicine, Ufuk University, Ankara, Turkey
2 shared publications - Abdulkadir Arpa
Department of Cardiology, Bismil State Hospital, Diyarbakır, Türkiye
1 shared publication - Adem Aktan
Department of Cardiology, Mardin Artuklu University, Mardin, Turkey
1 shared publication - Ahmet Ferhat Kaya
Department of Cardiology, Van Regional Education and Research Hospital, Van, Turkey
1 shared publication
Latest Publications
- Open Access
- 4 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 6047
Blood Pressure and Angina-Related Health Status During Benidipine Therapy: A Multicenter Real-World Cohort Study
Background: Benidipine is a long-acting calcium channel blocker used for the treatment of hypertension and chronic coronary syndrome. Although it effectively lowers blood pressure (BP), the relationship between BP reduction and improvement in angina-related health status during benidipine therapy remains uncertain. This study evaluated changes in BP and patient-reported angina-related health status in a large real-world cohort. Methods: This prospective, multicenter, observational cohort study included 1659 patients with hypertension and/or chronic coronary syndrome who underwent baseline clinical assessment before initiation of benidipine therapy and were reassessed after 3 months. Changes in systolic and diastolic BP and Seattle Angina Questionnaire-7 (SAQ-7) scores were evaluated. Multivariable linear regression analyses were performed to identify predictors of BP reduction and symptomatic improvement. A propensity score-matched analysis according to coronary artery disease (CAD) status was conducted to further explore differences in treatment response. Results: The mean age was 62.2 ± 12.2 years, and 54.0% of participants were women. Systolic BP decreased by 13.8 mmHg and diastolic BP by 6.7 mmHg (both p < 0.001). Mean SAQ-7 score increased by 8.1 points (p < 0.001), exceeding the established threshold for clinically meaningful improvement. Baseline SAQ-7 score showed the strongest association with change in SAQ-7, whereas baseline systolic BP was the strongest predictor of BP reduction. The correlation between changes in systolic BP and SAQ-7 was weak (r = 0.058, p = 0.023). In the propensity score-matched cohort (n = 732), BP reduction was similar regardless of CAD status, whereas improvement in SAQ-7 was greater in patients without obstructive CAD. Conclusions: In this multicenter real-world cohort, benidipine therapy was associated with significant BP reduction and clinically meaningful improvement in angina-related health status over 3 months. Symptomatic improvement showed only a weak association with BP reduction. These findings should be interpreted within the limitations of an observational study and warrant confirmation in controlled comparative studies.
- 4 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 6047
Open AccessBlood Pressure and Angina-Related Health Status During Benidipine Therapy: A Multicenter Real-World Cohort Study
Background: Benidipine is a long-acting calcium channel blocker used for the treatment of hypertension and chronic coronary syndrome. Although it effectively lowers blood pressure (BP), the relationship between BP reduction and improvement in angina-related health status during benidipine therapy remains uncertain. This study evaluated changes in BP and patient-reported angina-related health status in a large real-world cohort. Methods: This prospective, multicenter, observational cohort study included 1659 patients with hypertension and/or chronic coronary syndrome who underwent baseline clinical assessment before initiation of benidipine therapy and were reassessed after 3 months. Changes in systolic and diastolic BP and Seattle Angina Questionnaire-7 (SAQ-7) scores were evaluated. Multivariable linear regression analyses were performed to identify predictors of BP reduction and symptomatic improvement. A propensity score-matched analysis according to coronary artery disease (CAD) status was conducted to further explore differences in treatment response. Results: The mean age was 62.2 ± 12.2 years, and 54.0% of participants were women. Systolic BP decreased by 13.8 mmHg and diastolic BP by 6.7 mmHg (both p < 0.001). Mean SAQ-7 score increased by 8.1 points (p < 0.001), exceeding the established threshold for clinically meaningful improvement. Baseline SAQ-7 score showed the strongest association with change in SAQ-7, whereas baseline systolic BP was the strongest predictor of BP reduction. The correlation between changes in systolic BP and SAQ-7 was weak (r = 0.058, p = 0.023). In the propensity score-matched cohort (n = 732), BP reduction was similar regardless of CAD status, whereas improvement in SAQ-7 was greater in patients without obstructive CAD. Conclusions: In this multicenter real-world cohort, benidipine therapy was associated with significant BP reduction and clinically meaningful improvement in angina-related health status over 3 months. Symptomatic improvement showed only a weak association with BP reduction. These findings should be interpreted within the limitations of an observational study and warrant confirmation in controlled comparative studies.
- Open Access
- 5 June 2026
- Published by Galenos Yayinevi in Cardiovascular Surgery and Interventions
Gamma-glutamyl transferase levels and coronary artery disease severity assessed by SYNTAX score: Impact of premature atherosclerosis
Gamma-glutamyl transferase levels and coronary artery disease severity assessed by SYNTAX score: Impact of premature atherosclerosis - Cardiovascular Surgery and Interventions
- 5 June 2026
- Published by Galenos Yayinevi in Cardiovascular Surgery and Interventions
Open AccessGamma-glutamyl transferase levels and coronary artery disease severity assessed by SYNTAX score: Impact of premature atherosclerosis
Gamma-glutamyl transferase levels and coronary artery disease severity assessed by SYNTAX score: Impact of premature atherosclerosis - Cardiovascular Surgery and Interventions
- Open Access
- 19 January 2026
- Published by Galenos Yayinevi in Cardiovascular Surgery and Interventions
Comparative evaluation of clinical, hematological, and echocardiographic parameters in NSTE-MI patients undergoing CABG versus PCI
Comparative evaluation of clinical, hematological, and echocardiographic parameters in NSTE-MI patients undergoing CABG versus PCI - Cardiovascular Surgery and Interventions
- 19 January 2026
- Published by Galenos Yayinevi in Cardiovascular Surgery and Interventions
Open AccessComparative evaluation of clinical, hematological, and echocardiographic parameters in NSTE-MI patients undergoing CABG versus PCI
Comparative evaluation of clinical, hematological, and echocardiographic parameters in NSTE-MI patients undergoing CABG versus PCI - Cardiovascular Surgery and Interventions
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 41 (1)
Predictive Value of Uric Acid/Albumin Ratio for Postoperative Atrial Fibrillation Following Isolated Coronary Artery Bypass Surgery
Postoperative atrial fibrillation (POAF) is associated with an increased risk of morbidity and mortality. This study aims to investigate the predictive value of uric acid/albumin ratio (UAR) for POAF following isolated coronary artery bypass grafting (CABG). This retrospective study screened patients who underwent isolated CABG between June 2017 and January 2024. POAF was diagnosed using standard clinical criteria. UAR was calculated by dividing the uric acid level by the albumin value. This study included a total of 396 patients, who were categorized into two groups: POAF- and POAF+. Among them, 321 patients (mean age: 61.7 ± 10.8 years; 74.7% male) belonged to the POAF- group, while 75 patients (mean age: 71.3 ± 10.04 years; 68.1% male) were in the POAF+ group. While there were no significant differences observed between the groups in terms of sex, those in the POAF+ group were statistically older. The univariate and multivariate regression analyses revealed that age, C-reactive protein, hypertension, serum uric acid level, and UAR are independent risk factors for POAF. In the receiver operating characteristics analysis, the UAR (area under the curve [AUC]: 0.775) was found to be a better indicator compared to uric acid (AUC: 0.649) and serum albumin (AUC: 0.606), with a sensitivity of 70.5% and a specificity of 69.2%. UAR was shown to be an independent risk factor for POAF following isolated CABG.
- 1 January 2026
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 41 (1)
Open AccessPredictive Value of Uric Acid/Albumin Ratio for Postoperative Atrial Fibrillation Following Isolated Coronary Artery Bypass Surgery
Postoperative atrial fibrillation (POAF) is associated with an increased risk of morbidity and mortality. This study aims to investigate the predictive value of uric acid/albumin ratio (UAR) for POAF following isolated coronary artery bypass grafting (CABG). This retrospective study screened patients who underwent isolated CABG between June 2017 and January 2024. POAF was diagnosed using standard clinical criteria. UAR was calculated by dividing the uric acid level by the albumin value. This study included a total of 396 patients, who were categorized into two groups: POAF- and POAF+. Among them, 321 patients (mean age: 61.7 ± 10.8 years; 74.7% male) belonged to the POAF- group, while 75 patients (mean age: 71.3 ± 10.04 years; 68.1% male) were in the POAF+ group. While there were no significant differences observed between the groups in terms of sex, those in the POAF+ group were statistically older. The univariate and multivariate regression analyses revealed that age, C-reactive protein, hypertension, serum uric acid level, and UAR are independent risk factors for POAF. In the receiver operating characteristics analysis, the UAR (area under the curve [AUC]: 0.775) was found to be a better indicator compared to uric acid (AUC: 0.649) and serum albumin (AUC: 0.606), with a sensitivity of 70.5% and a specificity of 69.2%. UAR was shown to be an independent risk factor for POAF following isolated CABG.
- Open Access
- 25 December 2025
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 3 (3) , 118-121
Segmental Pulmonary Embolism Secondary to Iliac Vein Thrombosis in a Young Male with Behçet’s Disease: A Multimodal Diagnostic Case Report
Segmental Pulmonary Embolism Secondary to Iliac Vein Thrombosis in a Young Male with Behçet’s Disease: A Multimodal Diagnostic Case Report - Bulletin of Cardiovascular Academy
- 25 December 2025
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 3 (3) , 118-121
Open AccessSegmental Pulmonary Embolism Secondary to Iliac Vein Thrombosis in a Young Male with Behçet’s Disease: A Multimodal Diagnostic Case Report
Segmental Pulmonary Embolism Secondary to Iliac Vein Thrombosis in a Young Male with Behçet’s Disease: A Multimodal Diagnostic Case Report - Bulletin of Cardiovascular Academy
- 8 November 2025
- Published by SAGE Publications in Angiology
- Vol. 77 (7) , 828-835
Do We Know Enough About Radiation Exposure and Its Side Effects in Invasive Cardiological Procedures?
In the present study, radiation exposure rates of patients undergoing various invasive cardiological procedures, associated skin side effects, and the impact of radiation protection training for operators were evaluated. A total of 523 patients were included, of whom 206 (39.4%) were female and 317 (60.6%) were male. Radiation exposure levels and skin side effects were recorded. A positive correlation was observed between fluoroscopy dose (mGy) and patients’ body mass index (BMI) ( P < .001). Additionally, male patients were exposed to significantly higher radiation doses than females ( P < .003). Within 1 month post-procedure, skin-related side effects such as itching (6.3%) and dryness (5.4%) were reported. Patients undergoing more complex procedures, including percutaneous transluminal angioplasty (PTA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) imaging, had higher radiation doses and longer exposure times compared with other procedures. Following a seminar on radiation protection, a significant reduction in procedural radiation exposure was noted, indicating increased operator awareness. This study highlights the importance of procedural complexity, patient characteristics, and operator training in managing radiation risks during cardiological interventions.
- 8 November 2025
- Published by SAGE Publications in Angiology
- Vol. 77 (7) , 828-835
Do We Know Enough About Radiation Exposure and Its Side Effects in Invasive Cardiological Procedures?
In the present study, radiation exposure rates of patients undergoing various invasive cardiological procedures, associated skin side effects, and the impact of radiation protection training for operators were evaluated. A total of 523 patients were included, of whom 206 (39.4%) were female and 317 (60.6%) were male. Radiation exposure levels and skin side effects were recorded. A positive correlation was observed between fluoroscopy dose (mGy) and patients’ body mass index (BMI) ( P < .001). Additionally, male patients were exposed to significantly higher radiation doses than females ( P < .003). Within 1 month post-procedure, skin-related side effects such as itching (6.3%) and dryness (5.4%) were reported. Patients undergoing more complex procedures, including percutaneous transluminal angioplasty (PTA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) imaging, had higher radiation doses and longer exposure times compared with other procedures. Following a seminar on radiation protection, a significant reduction in procedural radiation exposure was noted, indicating increased operator awareness. This study highlights the importance of procedural complexity, patient characteristics, and operator training in managing radiation risks during cardiological interventions.
- 6 May 2024
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 2 (1) , 1-5
Does Angiotensin Receptor Blocker Therapy Increase The Risk of Cancer?
- 6 May 2024
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 2 (1) , 1-5
Does Angiotensin Receptor Blocker Therapy Increase The Risk of Cancer?
- 16 January 2024
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 1 (3) , 82-93
Effects of Diabetic and Prediabetic Status on Cardiac Autonomic Function
- 16 January 2024
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 1 (3) , 82-93
Effects of Diabetic and Prediabetic Status on Cardiac Autonomic Function
- Open Access
- 27 October 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (43) , e35589
Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study
Heart failure is an increasing public health issue with substantial morbidity and mortality rates. This study aimed to evaluate the efficacy, safety, and long-term outcomes of angiotensin receptor neprilysin inhibitor (ARNi) in the treatment of heart failure with reduced ejection fraction (HFrEF) 5 years after treatment initiation. This retrospective study analyzed a cohort of 75 patients diagnosed with HFrEF over a period of 5 years after the initiation of ARNi therapy. The initial clinical condition, laboratory and echocardiographic measurements including left ventricular ejection fraction (LVEF), New York Heart Association functional classes (NYHA-FC) and the prognostic nutritional index were compared to the corresponding values obtained after a 5-year period of ARNi therapy. In addition, the number of annual hospitalizations, mortality rates and any history of adverse effects during the follow-up period were recorded. The N-terminal pro-brain natriuretic peptide (NT-proBNP) level, LVEF, and NYHA-FC values demonstrated significant improvement at the end of the 5-year follow-up period (all parameters, P < .001). Although the observed increase in the prognostic nutritional index was not statistically significant (P = .077), it is worth noting. A significant reduction in daily diuretic doses and hospitalizations due to heart failure was observed following the use of ARNi (all comparisons, P < .001). The prevalence of hypotension was around 16% (being symptomatic in 4%), making it the most frequently observed adverse event. The 5-year cardiovascular mortality rate was 17.3%. The use of ARNi in HFrEF patients was associated with a notable improvement in NYHA-FC, LVEF, and NT-proBNP levels in the long-term, while also leading to a better nutritional status and reduced need for diuretics and annual hospitalization. Additionally, ARNi usage has been associated with improved nutritional status, decreased reliance on diuretics, and reduced frequency of annual hospitalizations. These effects were associated with a lack of significant increase in adverse effects. These results may contribute to a better understanding of ARNi’s long-term effects on patient outcomes.
- 27 October 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (43) , e35589
Open AccessLong-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study
Heart failure is an increasing public health issue with substantial morbidity and mortality rates. This study aimed to evaluate the efficacy, safety, and long-term outcomes of angiotensin receptor neprilysin inhibitor (ARNi) in the treatment of heart failure with reduced ejection fraction (HFrEF) 5 years after treatment initiation. This retrospective study analyzed a cohort of 75 patients diagnosed with HFrEF over a period of 5 years after the initiation of ARNi therapy. The initial clinical condition, laboratory and echocardiographic measurements including left ventricular ejection fraction (LVEF), New York Heart Association functional classes (NYHA-FC) and the prognostic nutritional index were compared to the corresponding values obtained after a 5-year period of ARNi therapy. In addition, the number of annual hospitalizations, mortality rates and any history of adverse effects during the follow-up period were recorded. The N-terminal pro-brain natriuretic peptide (NT-proBNP) level, LVEF, and NYHA-FC values demonstrated significant improvement at the end of the 5-year follow-up period (all parameters, P < .001). Although the observed increase in the prognostic nutritional index was not statistically significant (P = .077), it is worth noting. A significant reduction in daily diuretic doses and hospitalizations due to heart failure was observed following the use of ARNi (all comparisons, P < .001). The prevalence of hypotension was around 16% (being symptomatic in 4%), making it the most frequently observed adverse event. The 5-year cardiovascular mortality rate was 17.3%. The use of ARNi in HFrEF patients was associated with a notable improvement in NYHA-FC, LVEF, and NT-proBNP levels in the long-term, while also leading to a better nutritional status and reduced need for diuretics and annual hospitalization. Additionally, ARNi usage has been associated with improved nutritional status, decreased reliance on diuretics, and reduced frequency of annual hospitalizations. These effects were associated with a lack of significant increase in adverse effects. These results may contribute to a better understanding of ARNi’s long-term effects on patient outcomes.
- 20 October 2023
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 1 (1) , 17-20
Medical Problems Experienced by People with Cardiac and Non-cardiac Chronic Diseases During the COVID-19 Pandemic
- 20 October 2023
- Published by Galenos Yayinevi in Bulletin of Cardiovasculer Academy
- Vol. 1 (1) , 17-20
Medical Problems Experienced by People with Cardiac and Non-cardiac Chronic Diseases During the COVID-19 Pandemic